Biotest AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIESF research report →
Price Chart
About the company
Biotest Aktiengesellschaft, a German biopharmaceutical company established in Dreieich in 1946, specializes in the research, development, production, and global commercialization of advanced biological therapeutics. Its operations are organized into key segments: Therapy, Plasma & Services, and Other. The company’s primary focus areas encompass critical medical needs within hematology (blood disorders), clinical immunology, and intensive care medicine.
- CEO
- Jorg Schuttrumpf
- IPO
- 2014
- Employees
- 2,495
- HQ
- Dreieich, DE
Get TickerSpark's AI analysis on BIESF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.60B
- P/E
- 48.06
- PEG
- -0.42
- P/S
- 2.18
- P/B
- 2.40
- EV/EBITDA
- 17.22
- Div Yield
- 0.00%
- Gross Margin
- 30.82%
- Op Margin
- 13.01%
- Net Margin
- 3.64%
- ROE
- 5.13%
- ROIC
- 4.18%
Latest fiscal year · YoY change
- Revenue
- $648.66M-10.7%
- Gross Profit
- $61.88M-72.4%
- Op Income
- $-48,581,797
- Net Income
- $-70,673,520-367.7%
- EPS
- $-1.79-352.1%
- OCF Growth
- -335.9%
- FCF Growth
- -580.9%
- 52W High
- $32.00
- 52W Low
- $30.48
- 50D MA
- $32.00
- 200D MA
- $30.98
- Beta
- 0.17
- RSI (14)
- 100
- Avg Volume
- 75
No earnings-call transcripts are available for BIESF yet.
- Free Float
- 40.0%
- Shares Outstanding
- 49.99M
- Float Shares
- 20.01M
Our BIESF coverage
Recent articles, reports, and earnings notes.
No research on BIESF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIESF report →